drugset / Trial / NCT00660101
Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To determine if a vaccine made from the patient's own tumor tissue can stimulate an immune response against the patient's tumor cells. To determine the safety of the vaccine.
Timeline
- Start
- 2008-06
- Primary completion
- 2015-12
- Completion
- 2016-01
Publications
- Background Dunton CJ, Carlson JA, King SA, Bloome E, Neufeld J, Berd D. Immunological and clinical effects of autologous hapten-modified vaccine in patients with advanced ovarian carcinoma., 19: Abstract 1828 ed 2000. p. 466a.
- Background Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol. 2004 Feb 1;22(3):403-15. doi: 10.1200/JCO.2004.06.043. Epub 2003 Dec 22.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OVax | Vaccine | 500000 cells | Intrathecal |
| Subject | OVax | Vaccine | 2.5e+06 cells | Intrathecal |
| Subject | OVax | Vaccine | 5e+06 cells | Intrathecal |